anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composition for preventing and treating diseases related to fat liver is provided to inhibit the synthesis of lipid in serum and liver using complex herb extract containing a Coriolus versicolor and Astragalus membranaceus Bunge. A composition for preventing and treating fat liver diseases comprises a complex herb extract of Coriolus versicolor and Astragalus membranaceus Bunge as an active ingredient in a ratio of 0.1-10:1. The composition further comprises one or more herb extracts selected from a Schizandrae Fructus and artemisiae capillaries herba. The extract is crude extract, low alcohol insoluble fraction extract or non-ionic solvent soluble extract. The non-ionic solvent soluble extract is obtained by fraction with non-ionic solvent of hexane, chloroform, dichloromethane or ethylacetate. The fat liver diseases are alcoholic steatosis, vial coal steatosis, nutritional steatosis, inanition steatosis, adiposity steatosis or diabetic splenocyte steatosis.
PURPOSE: To obtain an adhesive tablet, comprising a hydrophilic tablet core containing baclofen and an excipient such as a swellable vinyl polymer, as necessary, a hydrophobic coating covering the tablet core and capable of maintaining the drug concentration at a therapeutic level for a long time without remarkably raising the concentration in blood plasma. CONSTITUTION: This adhesive tablet comprises a hydrophilic tablet core, containing baclofen useful as an antispasmodic agent or its salt and a swellable vinyl polymer as an excipient (e.g. an acrylic acid polymer or a vinylpyrrolidone polymer having 8.0×10<5> to 1.0×10<6> average molecular weight), galactomannan (e.g. guar gum) and/or a pharmaceutically permissible wax and/or glyceride or hydrogenated glyceride and having the top surface bondable to a receiving mucous membrane in oral cavity and a hydrophobic coating covering parts other than surfaces for the drug release (e.g. polyethylene glycol having film- forming properties). The composition is used by bonding thereof to the mucous membrane in the oral cavity.
The invention relates to the field of medical technologies, and particularly relates to a control method for a traditional Chinese medicine prescription preparation extracting and concentrating process and quality homogenization. Quality stabilization and homogenization is one of basic properties of drugs. According to the invention, the traditional Chinese medicine prescription preparation extracting and concentrating process (I + W) is standardized, a quality stabilization and homogenization control method implemented by taking the amount and concentration of extracted liquid as assessment indexes is established, and conventional five technological condition parameters of traditional Chinese medicine extraction are cleared, wherein the extracting time is determined by test. An automatic concentration detection and control system for concentrated solutions is increased, so that concentrated solution with the technological design concentration is automatically discharged in time, thereby shortening the heated time of an extracting solution, and increasing the medicinal composition retention rate of the extracting solution. Through continuous reflux extraction, the solvent can be reduced by 40%, thereby achieving the purposes of energy conservation, emission reduction and consumption reduction. If the aqueous extract rate of decoction dregs after alcohol extraction is more than or equal to 2%, the decoction dregs are subjected to a water-warm immersion or forced circulating extraction process, so that the ratio of extraction can be increased by more than or equal to 2%, and the transfer rate of water-soluble ingredients can be increased by more than or equal to 5%.
Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
BACKGROUND: Head and neck cancer (HNC) is the 7th most common cancer worldwide, and treatment often involves surgery. HNC surgery is intensive, complications are common, and quality of life (QOL) is negatively impacted. Support must be expanded to not only help patients survive HNC but to recover faster and live well following surgery. Prehabilitation, or optimizing a patient's condition before surgery, is a key opportunity to integrate supportive care early in the clinical care pathway for this underserved patient group. RESEARCH DESIGN AND METHODS: Using a mixed-methods approach, the aims of this hybrid implementation-effectiveness study are to (i) implement a multiphasic exercise prehabilitation program for HNC patients in a real-world setting and describe factors influencing implementation across the phases; (ii) determine the safety and tolerability of a multiphasic exercise prehabilitation program for HNC patients; (iii) explore the potential benefits of a multiphasic exercise prehabilitation program for HNC patients, and (iv) build a systematic screening and referral pathway into exercise oncology resources post-operatively. Outcomes are detailed below and include patient-reported outcomes, physical function, mobility (step count) and hospital length of stay.
Children will receive the EF training intervention, which will be delivered in a telehealth format across 10 sessions (1 1-hour session per week for 10 weeks), targeting core EF components including inhibitory control, attention shifting, and working memory. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.
This is a multicenter, randomized, open-label, cross-over Phase 3 study evaluating hyperpolarized 129Xe gas MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function. This study will enroll subjects being evaluated for possible lung resection surgery (i.e. segmentectomy, lobectomy, or pneumonectomy). Subjects will have both a 129Xe MRI and 133Xe scintigraphy image. The vast differences in technique for obtaining hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy make it impossible to blind study procedures. However, all image interpretation will be performed by personnel blinded to the subject's medical history and all study assessments.
The invention provides a collagen colloidal component for cleaning skin. It contains 40-60%(w/v) collagen in 60-80%(v/v) water-alcoholic solution. The collagen colloidal component is easy to be smeared on the skin due to its small viscosity. The collagen colloidal component has high drying rate so that it has excellent acne removal force without long time waiting. The invention also provides a peel-off style collagen mask kit comprising the collagen colloidal component and a sheet support capable of bonding the collagen colloidal component for forming a peel-off collagen mask. It has advantages of fast-drying, easy-removing, no hurt for skin and proper adhesion. It can clean skin pores effectively and pull out acne in use.
Participants will be administered Setanaxib 800 mg twice daily. Participants will also be administered Pembrolizumab 200 mg intravenously every 3 weeks.
PURPOSE:To provide an agent for improving hepatic function, containing dolichol and/or its pharmacologically permissible ester as active component, having low side effect and toxicity and exhibiting mild physiological effect. CONSTITUTION:The objective hepatic function-improving agent contains the compound of formula I (group of formula II is trans-isoprene unit; group of formula III is cis-isoprene unit; n is integer of 12-18) and/or its pharmacologically permissible salt as an active component. Since the agent has the above activity, it is useful as a remedy for improving the hepatic function of a person having lowered physical strength, especially of an aged person or patient of grave disease. It is administered at a dose of generally 0.05-1,000mg/kg daily, preferably 0.1-100mg/kg daily, especially 0.2-50mg/kg daily in 1-several doses. The compound of formula I can be produced e.g. by extracting from the organ of mammal.
Integrase strand transfer inhibitors are one of the newest class of antiretroviral drugs. This class of drugs inhibit the catalytic activity of HIV-1 integrase, an HIV-1-encoded enzyme required for viral replication \[1\]. Inhibition of integrase prevents covalent insertion of unintegrated, linear HIV-1 DNA into the host cell genome, therefore preventing the formation of HIV-1 provirus. RAL, the first agent in its class, was initially approved in 2007 for use in patients harboring drug-resistant HIV \[2\]. More recently, the FDA has expanded the indication for RAL use in HIV-infected patients who are antiretroviral naïve \[3\]. The currently approved dose is 400 mg twice daily. The RAL area-under-the-curve (AUC) and Cmax increase in a dose-dependent fashion over the range of 100 mg to 1,600 mg. With twice-daily dosing, PK steady state is achieved within approximately the first 2 days. Considerable variability was observed in the PK of raltegravir in clinical trials. In clinical trial participants receiving twice-daily RAL 400 mg, drug exposures were characterized by a geometric mean AUC within the first 12 hours of 14.3 mcM(hr) and a plasma concentration at 12 hours of 142 nM \[3\]. RAL at concentrations of 6 to 50 nM resulted in 95% inhibition (EC95) of viral spread in mitogen-activated human peripheral blood mononuclear cells (PBMCs) infected with diverse, primary clinical isolates of HIV-1, including isolates resistant to reverse transcriptase inhibitors and protease inhibitors (PIs).

The absolute bioavailability of RAL has not been established. RAL is approximately 83% bound to human plasma protein over the concentration range of 2 to 10 mcM. The apparent terminal half-life of RAL is approximately 9 hours, with a shorter alpha-phase half-life (about 1 hour), accounting for much of the AUC. Determination of drug levels to guide treatment of HIV infection is available for protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) but is not yet considered standard of care \[4,5\]. RAL is associated with potent performance against HIV in treatment-naïve patients and those with limited treatment options, potentially because of its binding interaction with the HIV preintegration complex. When RAL binds to the complex, the drug dissociates at a rate slower than the half-life of the complex itself, which makes binding essentially irreversible. Thus, the efficacy of RAL may be dependent on intracellular binding levels of the drug to the preintegration complex, rather than on the plasma concentrations of RAL. Because of this, we postulate that intracellular concentrations of RAL are more likely to correlate with biological activity against HIV. Moreover, if pharmacokinetic behavior can be predicted, and depending on the trough concentrations observed, the drug might be suitable for different dosing approaches including once a day administration. This would create more flexibility for patients, and the chance to improve adherence.
PROBLEM TO BE SOLVED: To obtain a composition suitable for external use such as cosmetics and medicines for external use, capable of sufficiently exhibiting actions which a medicine essentially has by combining an extract of the root bark or the trunk bark of Acanthopanax gracilistylus with a specific medicine. SOLUTION: This medicine comprises an extract of the root bark or the trunk bark of Acanthopanax gracilistylus and a medicine selected from a tyrosinase activity inhibitor, a cell activator, an antiinflammatory agent and a humectant. A vitamin C, a glutathione, a cystine, glabrene, etc., are used as the tyrosinase activator. A deoxyribonucleic acid, adenosine triphosphate, a ribonucleic acid, etc., are used as the cell activator. Glycyrrhizinic acid, mefenamic acid, indomethacin, ibuprofen, etc., are used as antiinflammatory agent. Hyaluronic acid, chondroitinsulfuric acid, dermatan sulfate, etc., are used as the humectant. The content of the dermatan sulfate is about 0.00001-1wt.% calculated as a dried solid content.  The amount of the tyrosinase activator inhibitor blended is about 0.0001-10wt.% calculated as a dried solid content, that of the cell activator is about 0.001-5wt.% and that of the antiinflammatory agent is about 0.0001-5wt.%.
<P>PROBLEM TO BE SOLVED: To stabilize vitamin C and to exhibit excellent beautiful skin effect without adding an artificial chemical substance for stabilizing vitamin C in fruit juice in a skin cosmetic containing acerola fruit juice.  <P>SOLUTION: The skin cosmetic comprises acerola fruit juice and mineral water containing sodium hydrogencarbonate. Acerola fruit juice is obtained by squeezing acerola fruit washed with an aqueous solution of citric acid. The cosmetic contains 10-60 wt.% of acerola fruit juice. Mineral water may contain metasilicic acid or a metasilicate besides sodium hydrogencarbonate.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention relates to a formula of natural plant components for promoting hair growth. The formula contains qianzhen extract. The invention also provides a preparation method and application of the formula. The formula of the natural plant components, provided by the invention, has the advantages that a skin irritation test and a skin acute toxicity test prove that the formula is non-irritant to the skin and can not generate acute toxicity response, so that the formula is safe. An animal test and a human test prove that the formula can effectively promote hair growth and prevent alopecia. Moreover, the formula has a hair blacking function for some patients.
Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
The dyads will receive traditional educational treatment only and will complete the questionnaires after 3, 6, 9 and 12 months follow-up post-intervention. Enrolled dyads will be monitored by the research team responsible for recruitment and follow-up.
Parkinson's disease (PD) is a prevalent progressive and multifactorial neurodegenerative disorder. Cordycepin is known to exhibit antitumor, anti-inflammatory, antioxidative stress, and neuroprotective effects; however, few studies have explored the neuroprotective mechanism of cordycepin in PD. Using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, we investigated the impact of cordycepin on PD and its underlying molecular mechanisms. The findings indicated that cordycepin significantly mitigated MPTP-induced behavior disorder and neuroapoptosis, diminished the loss of dopaminergic neurons in the striatum-substantia nigra pathway, elevated striatal monoamine levels and its metabolites, and inhibited the polarization of microglia and the expression of pro-inflammatory factors. Subsequent proteomic and phosphoproteomic analyses revealed the involvement of the MAPK, mTOR, and PI3K/AKT signaling pathways in the protective mechanism of cordycepin. Cordycepin treatment inhibited the activation of the PI3K/AKT/mTOR signaling pathway and enhanced the expression of autophagy proteins in the striatum and substantia nigra. We also demonstrated the in vivo inhibition of the ERK/JNK signaling pathway by cordycepin treatment. In summary, our investigation reveals that cordycepin exerts neuroprotective effects against PD by promoting autophagy and suppressing neuroinflammation and neuronal apoptosis by inhibiting the PI3K/AKT/mTOR and ERK/JNK signaling pathways. This finding highlights the favorable characteristics of cordycepin in neuroprotection and provides novel molecular insights into the neuroprotective role of natural products in PD.
Breathe2Relax is a mobile application that instructs users on diaphragmatic breathing, a coping tool in which slow breathing through the diaphragm reduces anxiety. Participants in the control condition will download Breathe2Relax to their smartphones and receive short message service (SMS) reminders to engage with the app. The control intervention is expected to reduce symptoms, but not as much as the cognitive-behavioral therapy strategies taught in RISE Guide.
Information for Patients   
Patients should be advised to take nitrofurantoin with food (ideally breakfast and dinner) to further enhance tolerance and improve drug absorption. Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms occur during therapy. 

Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking nitrofurantoin.

Patients should be counseled that antibacterial drugs including nitrofurantoin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When nitrofurantoin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by nitrofurantoin or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
The invention discloses pseudomonas aeruginosa and a marine mammal vaccine containing the same. The used strain is pseudomonas aeruginosa DCP1 strain separated from marine mammals, and the preservation number is CGMCC NO. 15418. The invention also provides a marine mammal vaccine, the active ingredient of which is the inactivated pseudomonas aeruginosa antigen of the marine mammal. The invention also provides a preparation method of the marine mammal vaccine, which comprises the processes of strain separation, identification, purification, antigen preparation, vaccine preparation and the like. The pseudomonas aeruginosa inactivated vaccine prepared by the invention is safe and reliable, can obviously improve the antibody level, and has wide application prospect.
PROBLEM TO BE SOLVED: To produce an alum block excellent in transparency, impact resistance and shearing strength, good in stability against weathering at the time of preservation and good in solubility to water by blending starch or glycerine to the alum and crystallizing this mixture. SOLUTION: In a hot soln. dissolved with alum, 0.05-5wt.% starch or glycerine per alum is added so as to make them dissolved or dispersed uniformly and injected into a molding vessel. The soln. is cooled while preventing an evaporation of water from an opening surface by sealing the opening surface of the hot soln. with liq. or solid to grow an alum crystal in block-like and to produce the alum block.
BACKGROUND AND AIMS: Inflammatory cells within atherosclerotic lesions secrete proteolytic enzymes that contribute to lesion progression and destabilization, increasing the risk for an acute cardiovascular event. Elastase is a serine protease, secreted by macrophages and neutrophils, that may contribute to the development of unstable plaque. We previously reported interaction of endogenous protease-inhibitor proteins with high-density lipoprotein (HDL), including alpha-1-antitrypsin, an inhibitor of elastase. These findings support a potential role for HDL as a modulator of protease activity. In this study, we test the hypothesis that enhancement of HDL-associated elastase inhibitor activity is protective against atherosclerotic lesion progression.
METHODS: We designed an HDL-targeting protease inhibitor (HTPI) that binds to HDL and confers elastase inhibitor activity. Lipoprotein binding and the impact of HTPI on atherosclerosis were examined using mouse models. Histology and immunofluorescence staining of aortic root sections were used to examine the impact of HTPI on lesion morphology and inflammatory features.
RESULTS: HTPI is a small (1.6 kDa) peptide with an elastase inhibitor domain, a soluble linker, and an HDL-targeting domain. When incubated with human plasma ex vivo, HTPI predominantly binds to HDL. Intravenous administration of HTPI to mice resulted in its binding to plasma HDL and increased elastase inhibitor activity on isolated HDL. Accumulation of HTPI within plaque was observed after administration to Apoe-/- mice. To examine the effect of HTPI treatment on atherosclerosis, prevention and progression studies were performed using Ldlr-/- mice fed Western diet. In both study designs, HTPI-treated mice had reduced lipid deposition in plaque.
CONCLUSIONS: These data support the hypothesis that HDL-associated anti-elastase activity can improve the atheroprotective potential of HDL and highlight the potential utility of HDL enrichment with anti-protease activity as an approach for stabilization of atherosclerotic lesions.
Milk thistle (MT) has been historically used to treat patients with liver diseases, and has been shown to have antioxidant, anti inflammatory, and hepatoprotective properties. It may also have direct anticancer effects through inhibition of growth factors and promotion of cell cycle arrest. MT has been shown to improve LFTs in several studies of patients with cirrhosis. To our knowledge, there have been no published trials evaluating the clinical efficacy of MT in advanced HCC. We therefore propose a phase I study to identify the maximum tolerated dose (MTD) of silybinphosphatidylcholine (a commercially available preparation with increased bioavailability), in patients with advanced HCC. We will use a traditional dose escalation, open label design with a study intervention period of 3 months, followed by one year of observation, with a maximum total of 30 subjects, evaluating a dose range between 1 to 12 gm Siliphos. The data obtained from this study will be utilized in the future to evaluate MT efficacy in reducing liver function tests in advanced HCC, which will have significant implications in its use as a potential adjunctive agent in patients with currently limited treatment options.